Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALB | P02768 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13532236 | 0.81 | ALDH1A1 (0.33) | ALDH1A1LMNA | |
| SCHEMBL20058766 | 0.76 | DOT1L (0.37) | — | |
| SCHEMBL13532219 | 0.76 | DOT1L (0.37) | — | |
| SCHEMBL13696066 | 0.76 | DOT1L (0.37) | — | |
| SCHEMBL12388340 | 0.73 | EGFR (0.31) | — | |
| SCHEMBL14642541 | 0.71 | — | — | |
| SCHEMBL19412694 | 0.70 | PNP (0.30) | — | |
| SCHEMBL881700 | 0.69 | TLR7 (0.40) | ALDH1A1LMNAALBMAPK1 | |
| SCHEMBL12389151 | 0.66 | LMNA (0.31) | LMNA | |
| SCHEMBL14140988 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | EIF2AK2, ZC3HAV1, MAVS | ALDH1A1 2126/4885LMNA 2472/4885ALB 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.